Citi analyst Vineet Agrawal lowered the firm’s price target on MorphoSys to EUR 12 from EUR 16 and keeps a Sell rating on the shares. The analyst believes 2023 and 2024 consensus estimates for Monjuvi sales look 15%-25% too high. The company’s market opportunity in relapsed or refractory diffuse large B-cell lymphoma setting may "shrink further," writes Agrawal, who sees a lack of catalysts for MorphoSys shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MOR:
- MorphoSys downgraded to Sell from Neutral at Goldman Sachs
- Hookipa Pharma promotes Schlienger to CMO, appoints Peters to board
- MorphoSys Nosedives after Alzheimer’s Drug Fails Trial
- Roche says Phase 3 Alzheimer’s studies failed to meet primary endpoint
- MorphoSys sinks after partner Roche’s Alzheimer’s study fails
